UVA’s Pioneering Trial Offers Hope for Sepsis Lung Failure
The University of Virginia has opened a first-in-human program for hCitH3-mAb, a monoclonal antibody intended to neutralize citrullinated histone...
Vagus Nerve Device Studied as Adjunctive PTSD Treatment
The initiative will enroll up to 40 adults with PTSD for 12 weeks of adjunctive treatment with gammaCore Sapphire,...
Important Aligos Phase 2 B-SUPREME Study Progress Revealed
Aligos has enrolled 144 patients into its Phase 2 B-SUPREME study of pevifoscorvir sodium (ALG-000184) in chronic hepatitis B,...
Exicure to Reveal Latest Burixafor Phase 2 Trial Data
Exicure’s open-label, multicenter Phase 2 trial in multiple myeloma reported that 89.7% of patients met the study’s primary mobilization...
Comphya CaverSTIM Study Published in BJUI, Nature Urology
In a first-in-human pilot of 10 preoperatively potent men undergoing nerve‑sparing robotic radical prostatectomy, Comphya’s implantable cavernous nerve neurostimulator...
Nxera Pharma Reports Successful Daridorexant Phase 3 Trial
Daridorexant 50 mg met the primary endpoint of change from baseline in subjective total sleep time at Day 28...
New Study IDs Way to Prevent and Treat Lyme Arthritis
In preclinical Lyme disease models, subtle alterations to the Borrelia burgdorferi peptidoglycan nearly eliminated arthritis despite ongoing infection at...
BioAge Announces Promising New Trial for Macular Edema Drug
In preclinical models of diabetic macular edema, oral BGE-102 nearly eliminated retinal vascular leakage and preserved up to 90%...
Tiziana Life Sciences Publishes Intranasal Foralumab Study
In an open-label study of 10 patients with non-active secondary progressive multiple sclerosis, intranasal foralumab showed no serious or...
Clinical Trial Tests D-Serine to Modify Parkinson’s Disease
SPARK NS and Haukeland University Hospital will run a randomized, double-blind, placebo-controlled Phase 2b trial of oral D-serine in...
